Sorrento Therapeutics

Sorrento Therapeutics is a company listed under the stock ticker SRNE (US).

View the org chart displaying its 25 main executives

Most searched biographies at Sorrento Therapeutics

• Henry Ji, Chairman, President and Chief Executive Officer
• Jaisim Shah, Director
• Yue Wu, Director

Create your alert
to follow the executive moves at Sorrento Therapeutics.

Sorrento Therapeutics has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Sorrento Therapeutics

• Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster | Sorrento Therapeutics
• Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc. | Sorrento Therapeutics
• News Releases | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors | Sorrento Therapeutics
• Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. | So
• Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes | Sorrento Therapeutics
• Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans | Sorrento Therapeutics
• View more press releases Close

Social media about Sorrento Therapeutics

• Sorrento Therapeutics on Wikipedia, Google News & Yahoo Finance
• Sorrento Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Henry Ji

Call Sorrento Therapeutics at +1 858...

View the org chart

Register to receive your alert

Report an error